Purification process and formulation of recombinant anti rhd monoclonal antibodies
Patent Information
- Application Number
- AU2025223299
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-14
- Filing Date
- 2025-02-08
- Publication Date
- 2026-09-10
AI Technical Summary
Existing purification processes for recombinant anti-Rhesus D monoclonal antibodies face challenges in effectively removing high molecular weight (HMW) and low molecular weight (LMW) impurities, leading to suboptimal product quality and stability.
An improved purification process involving affinity chromatography, low pH inactivation, anion exchange chromatography, cation exchange chromatography, virus/nanofiltration, and ultrafiltration is employed to achieve thorough purification and enhance product quality and stability.
The process achieves a yield of at least 50% with HMW impurities less than 0.5% and LMW impurities less than 1.5%, resulting in a stable formulation with improved shelf life and compliance with international regulatory standards.
Smart Images

Figure 00000045_0000 
Figure 00000046_0000 
Figure 00000047_0000
